Toshihiko Doi
Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units.
Toshihiko Doi directs early drug development at NCC East, where he led the first-in-human trial of DS-8201 (trastuzumab deruxtecan) and numerous other first-in-class studies in solid tumours.
Pages like this
not linked directly; found by shared links- PersonNoboru Yamamoto
Shares Daiichi Sankyo, National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonKan Yonemori
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonKoichi Goto
Shares National Cancer Center Hospital East, National Cancer Center Hospital, Trastuzumab deruxtecan.
- PersonBob T. Li
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- IdeaContinuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonKohei Shitara
Shares National Cancer Center Hospital East, National Cancer Center Hospital, Trastuzumab deruxtecan.
- InstitutionPharmaceuticals and Medical Devices Agency
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).